Block view
- Organisation
- Théorie
- Pratique
- Autres
- Crédits
Block 1
Information
Professor Ph HUBERT
Analytical chemistry
B36 - 4000 Liege
Phone number: 04/366 43 16
e-mail address: Ph.Hubert@uliege.be
Analytical chemistry
B36 - 4000 Liege
Phone number: 04/366 43 16
e-mail address: Ph.Hubert@uliege.be
Collegiality
For ULiège: Vincent BIERLAIRE, Bruno BOULANGER, Raphael DENOOZ, Laurence DENIS, Brigitte EVRARD, Marianne FILLET, Michel FREDERICH, Philippe HUBERT, Roland MARINI, Dominique MARTIN, Bernard PIROTTE, Régis RADERMECKER, Jean-Michel VANDERHOFSTADT, Eric ZIEMONS.
For the ULB: Patrick DI STEFANO, François DUFRASNE, Walid EL AZAB, Véronique FONTAINE, Jonathan GOOLE, Anne LENAERS, Hugues MALONNE, Thierry SCHURMANS, Caroline STEVIGNY, Pierre VAN ANTWERPEN, Francis VANDERBIST, Karen VAN MALDEREN, David VERMIJLEN, Zéna WIMANA .
For the UCL: Catherine DRUEZ, Laure ELENS, Xavier MARCELIS, François-Xavier MATHY, Jacques POUPAERT, Thierry PRONCE, Joëlle LECLERCQ, Nevin SERBEST, Rita VANBEVER.
For the ULB: Patrick DI STEFANO, François DUFRASNE, Walid EL AZAB, Véronique FONTAINE, Jonathan GOOLE, Anne LENAERS, Hugues MALONNE, Thierry SCHURMANS, Caroline STEVIGNY, Pierre VAN ANTWERPEN, Francis VANDERBIST, Karen VAN MALDEREN, David VERMIJLEN, Zéna WIMANA .
For the UCL: Catherine DRUEZ, Laure ELENS, Xavier MARCELIS, François-Xavier MATHY, Jacques POUPAERT, Thierry PRONCE, Joëlle LECLERCQ, Nevin SERBEST, Rita VANBEVER.
| Code | Détails | Organisation | Théorie | Pratique | Autres | Crédits | |
|---|---|---|---|---|---|---|---|
| PHIN2004-1 | Active substances | TA | 6 | ||||
| Substances issues de recherches pharmacochimiques, part a | 10 | - | - | ||||
| Substances issues de recherches pharmacochimiques, part b
Françoise Dufrasne
| 5 | - | - | ||||
| Substances issues des biotechnologies
David Vermijlen
| 15 | - | - | ||||
| Substances d'origine naturelle, part a
Joëlle Quetin-Leclercq
| 5 | - | - | ||||
| Substances d'origine naturelle, part b
Caroline Stevigny
| 5 | - | - | ||||
| Produits radiopharmaceutiques
Zena Wimana
| 10 | - | - | ||||
| PHIN2008-2 | Clinical viewpoints | TA | 6 | ||||
| Métabolisme des médicaments et paramètres pharmacocinétiques
François-Xavier Mathy
| 20 | - | - | ||||
| Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques) | 15 | - | - | ||||
| Information et pharmacovigilance | 10 | - | - | ||||
| PHIN2013-2 | Quality assurance and pharmaceutical management | TA | 7 | ||||
| Principles of pharmaceutical management | 10 | - | - | ||||
| Quality assurance, part a : basic concepts and quality assurance organisation
Thierry Pronce
| 20 | - | - | ||||
| Quality assurance, part b: Qualification and validation approach and risk analysis
Xavier Marcelis
| 7,5 | - | - | ||||
| English applied to the pharmaceutical industry
Jacques Poupaert, Nevin Serbest
| 20 | - | - | ||||
| Pharmaceutical marketing | 7,5 | - | - | ||||
| PHIN2033-1 | Industrial pharmaceutical technology | TA | 8 | ||||
| Industrial pharmaceutical microbiology
Véronique Fontaine
| 15 | - | - | ||||
| Preformulation and selection of galenical forms
Jonathan Goole
| 15 | - | - | ||||
| Industrial production of galenical forms | 15 | - | - | ||||
| Industrial production of biomolecules
Rita Van Bever
| 15 | - | - | ||||
| Industrial aspects of technological development including packaging | 10 | - | - | ||||
| PHIN2023-1 | Drug analysis | TA | 7 | ||||
| Methods in pharmaceutical and biopharmaceutical analysis, part a : Detection of (bio)pharmaceutical products
Jean-Michel Kauffman, Pierre Van Antwerpen
| 10 | - | - | ||||
| Methods in pharmaceutical and biopharmaceutical analysis, part b : Preparation and separation of (bio) pharmaceutical products for quality control and pharmacokinetic study | 10 | - | - | ||||
| Methods in pharmaceutical and biopharmaceutical analysis, part c : Validation and qualification of equipment | 15 | - | - | ||||
| Methods in pharmaceutical and biopharmaceutical analysis, part d : Vibrational spectroscopy | 5 | - | - | ||||
| Statistical methods applied to the pharmaceutical industry
Laure Elens
| 15 | - | - | ||||
| Experimental planning and "quality by design" | 10 | - | - | ||||
| PHIN2029-2 | Regulation and the medical-social environment | TA | 8 | ||||
| Economic aspects of drug development | 10 | - | - | ||||
| Legislation and procedures applied to pharmaceutical industry, part a : legislation
Catherine Druez
| 10 | 5 | - | ||||
| Legislation and procedures applied to pharmaceutical industry, part b : patents and protection
Patrick Di Stefano
| 5 | - | - | ||||
| Macroeconomic environment and pharmaco-economics
Hugues Malonne
| 10 | - | - | ||||
| CTD File (Common Technical Document) | 15 | - | - | ||||
| Regulations of preclinical and clinical studies, part a : pharmaceutical toxicological files
Karen Van Malderen
| 15 | - | - | ||||
| Regulations of preclinical and clinical studies, part b : clinical studies
Anne Lenaers
| 5 | - | - | ||||
| Regulations of preclinical and clinical studies, part c : pediatric studies
Thierry Schurmans
| 2,5 | - | - | ||||
| Specific regulatory issues, part a : medicine and herbal dietary supplement | 5 | - | - | ||||
| Specific regulatory issues, part b : Preformulation and galenical development documentation
Francis Vanderbist
| 5 | - | - | ||||
| PHIN2032-1 | Visits and seminars organised in the pharmaceutical industry - [77,5h Visit]
Françoise Dufrasne, Marianne Fillet, Joëlle Leclercq, Rita Van Bever
| TA | - | - | [+] | 3 | |
| MTFE2000-1 | Final work
Françoise Dufrasne, Philippe Hubert, Joëlle Leclercq
| TA | - | - | - | 15 |